TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Apr 14, 2021 13:49 JST
Source:
Eisai
Eisai to Present Latest Data on Neurology Products and Pipelines at the American Academy of Neurology Annual Meeting
TOKYO, Apr 14, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company will conduct presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (development code: BAN2401), its dual orexin receptor antagonist lemborexant (product name: Dayvigo) and its antiepileptic drug perampanel (product name: Fycompa), at the Virtual American Academy of Neurology (AAN 2021) Annual Meeting from April 17 to 22, 2021.
As major presentations, an oral presentation regarding lecanemab will be given on the preliminary analysis for results of changes in brain-A beta levels and amyloid-related imaging abnormalities-edema (ARIA-E) as observed in subjects of the ongoing open-label extension of the Phase II study (Study 201) for early Alzheimer's disease (AD) patients. Poster presentations regarding lemborexant are also planned, including the results of a pilot study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment. Additionally, for perampanel, a global pooled analysis results from the real-world experiences including early adjunctive use or monotherapy will be presented at poster sessions.
Eisai considers neurology a therapeutic area of focus. Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with the disease and their families.
For more information, visit
https://www.eisai.com/news/2021/news202127.html
.
Source: Eisai
Sectors: BioTech
Copyright ©2021 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11 2021 09:00 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07 2021 10:08 JST
RESONA and Eisai Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia in Saitama Prefecture, Japan
April 28 2021 11:33 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
April 23 2021 13:55 JST
Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies
April 23 2021 12:02 JST
Notice Regarding Biogen's Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer's Disease
April 23 2021 08:07 JST
Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease
April 20 2021 08:23 JST
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
April 12 2021 12:16 JST
KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
March 31 2021 20:22 JST
Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Renal Cell Carcinoma in Japan
March 31 2021 20:18 JST
More Press release >>
Latest Press Release
Mitsubishi Power Achieves #1 Market Share Globally in the First Quarter of 2021 According to McCoy Power Report
May 13, 2021 18:29 JST
Showa Denko Announces 2021 First Quarter Financial Results
May 13, 2021 15:30 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony in Shimonoseki for Large Ferry Built for Meimon Taiyo Ferry
May 13, 2021 15:06 JST
MHI Thermal Systems fully revises a lineup of inverter multi-split air conditioners for buildings in its overseas markets
May 13, 2021 14:06 JST
MHI Thermal Systems Confirms Effectiveness of Air Purification Filtering Technology for Removal and Inactivation of SARS-CoV-2
May 12, 2021 12:17 JST
Collaboration with South Pole to Generate and Sell Carbon Credits from Carbon Removal Technologies
May 12, 2021 12:02 JST
Fujitsu Signs Strategic Collaboration Agreement with AWS to Accelerate Digital Transformation in the Mobility Industry
May 12, 2021 10:51 JST
Mitsubishi Power Receives Turnkey Order for 50MW Woody Biomass-fired Power Generation Facility
May 11, 2021 18:39 JST
Eisai's Statement of Commitment for Carbon Neutrality by 2040
May 11, 2021 10:00 JST
ENEOS and Toyota Come Together to Make Woven City the Most Hydrogen-Based Society
May 10, 2021 15:38 JST
Showa Denko Revises Forecast of Consolidated Performance and to Record Extraordinary Loss
May 10, 2021 11:30 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Priority Review From FDA for LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Applications
May 07, 2021 11:08 JST
Showa Denko and Infineon Technologies Conclude Supply Contract and Development Agreement
May 06, 2021 17:30 JST
NEC Develops Neuroscience-inspired AI Technology for Time Series Analysis
May 06, 2021 14:13 JST
NEC Contributes to Development of Artificial DNA Aptamer that Binds to the Novel Coronavirus (SARS-CoV-2)
May 06, 2021 11:27 JST
Synopsis 2021: Hot Trends - Join the Summit 1-5 June
May 04, 2021 09:00 JST
Hard-Fought Hypercar Win for Toyota Gazoo Racing
May 03, 2021 04:25 JST
Komatsu, NTT DOCOMO, Sony Semiconductor Solutions and Nomura Research Institute to Launch "EARTHBRAIN"
Apr 30, 2021 16:35 JST
Toyota Developing Hydrogen Engine Technologies Through Motorsports
Apr 30, 2021 14:20 JST
Toyota Global Sales and Production Secures 90 Percent Level Year-on-Year in FY2021
Apr 28, 2021 16:46 JST
More Latest Release >>